On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.

Subject to the satisfaction or waiver of customary closing conditions, Servier and Edgewise expect the transaction to close later in 2026.

The Wilson Sonsini team that advised Edgewise on the transaction includes:

Mergers & Acquisitions/Corporate 
Robert Ishii
Ross Tanaka
Tony Jeffries
David Adler
Alexander Dubose
Jayshawn Anderson

Technology Transactions 
Miranda Biven
Nellie Brutocao
Sarah Walker
Isaiah Loya
Kim Parry

Data, Privacy, and Cybersecurity
Matthew Staples
Michael S. O’Brien
Dan Shin

Employment Law
Jason Storck
Aren Balabanian

Tax
Myra Sutanto Shen
Anjali Krishnan

Antitrust and Competition
Jamillia Ferris
Michelle Yost Hale
Kimberley Biagioli
Laura Singer

Regulatory 
Joshua Gruenspecht
Eva Yin
Anne Seymour
Seth Cowell
Bryan Poellot

Patents and Innovations
Julia Minitti
Grant Margulieux
Steve Hanna

Employee Benefits and Compensation
Brandon Gantus
Michael Klippert
Jason Chan
Emma Wilcox
Han Bae

For more information, please see Edgewise’s news release. Additional information can be found in Edgewise’s 8-K filing with the U.S. Securities and Exchange Commission.